BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19147501)

  • 21. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.
    Toffalini F; Kallin A; Vandenberghe P; Pierre P; Michaux L; Cools J; Demoulin JB
    Haematologica; 2009 Aug; 94(8):1085-93. PubMed ID: 19644140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
    Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
    Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages.
    Arinobu Y; Mizuno S; Chong Y; Shigematsu H; Iino T; Iwasaki H; Graf T; Mayfield R; Chan S; Kastner P; Akashi K
    Cell Stem Cell; 2007 Oct; 1(4):416-27. PubMed ID: 18371378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
    Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
    Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia.
    Monma F; Nishii K; Lorenzo F; Usui E; Ueda Y; Watanabe Y; Kawakami K; Oka K; Mitani H; Sekine T; Tamaki S; Mizutani M; Yagasaki F; Doki N; Miyawaki S; Katayama N; Shiku H
    Eur J Haematol; 2006 Jan; 76(1):18-22. PubMed ID: 16343267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
    Li B; Zhang G; Li C; He D; Li X; Zhang C; Tang F; Deng X; Lu J; Tang Y; Li R; Chen Z; Duan C
    PLoS One; 2012; 7(4):e34912. PubMed ID: 22523564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
    Cooper S; Guo H; Friedman AD
    PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.
    Ibata M; Iwasaki J; Fujioka Y; Nakagawa K; Darmanin S; Onozawa M; Hashimoto D; Ohba Y; Hatakeyama S; Teshima T; Kondo T
    Cancer Sci; 2017 Feb; 108(2):200-207. PubMed ID: 27960034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
    Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
    Verstovsek S; Giles FJ; Quintás-Cardama A; Manshouri T; Huynh L; Manley P; Cortes J; Tefferi A; Kantarjian H
    Leuk Res; 2006 Dec; 30(12):1499-505. PubMed ID: 16682077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
    Yamada Y; Cancelas JA
    Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
    Yamada Y; Cancelas JA; Rothenberg ME
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.
    Stover EH; Chen J; Folens C; Lee BH; Mentens N; Marynen P; Williams IR; Gilliland DG; Cools J
    Proc Natl Acad Sci U S A; 2006 May; 103(21):8078-83. PubMed ID: 16690743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.
    Lee JS; Lee NR; Kashif A; Yang SJ; Nam AR; Song IC; Gong SJ; Hong MH; Kim G; Seok PR; Lee MS; Sung KH; Kim IS
    Front Immunol; 2020; 11():1258. PubMed ID: 32903598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
    Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eosinophilia in mast cell disease.
    Kovalszki A; Weller PF
    Immunol Allergy Clin North Am; 2014 May; 34(2):357-64. PubMed ID: 24745679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
    Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
    Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
    Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.